BioAtla (BCAB) Current Deferred Revenue (2020 - 2021)
BioAtla (BCAB) posted quarterly Current Deferred Revenue of $19.8 million for Q3 2021, little changed quarter-over-quarter from $19.8 million in Q2 2021.
BioAtla (BCAB) Current Deferred Revenue (2020 - 2021) Analysis & Trends
BioAtla's Current Deferred Revenue history runs 2 years deep, the most recent figure standing at $19.8 million for Q3 2021.
- In Q3 2021, Current Deferred Revenue changed N/A year-over-year to $19.8 million; the TTM figure through Sep 2021 stood at $19.8 million (changed N/A YoY), while the FY2020 annual figure was $19.8 million, changed N/A from the prior year.
- Current Deferred Revenue for Q3 2021 stood at $19.8 million, roughly flat from $19.8 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $19.8 million in Q4 2020, with the low at $393000.0 in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | BioAtla | 5.28 Mn | 5.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 19.80 Mn |
| Jun 30, 2021 | 19.81 Mn |
| Mar 31, 2021 | 393,000.00 |
| Dec 31, 2020 | 19.81 Mn |